ProgrammableMarketing/bridgebio.com (opens in a new tab)
PDF

Views

  • Plan
  • Roadmap
  • Research

On this page

  • The brief
  • Start here
  • Idea portfolio
  • Effort vs impact
  • This week · 6
  • This quarter · 10
  • Big bets · 3
  • Wildcards · 2
  • How we can help
Generated Oct 26, 2026 3 views
  1. Programmable
  2. Playbooks
  3. BridgeBio
BridgeBio logo

growth playbook · Oct 26, 2026

bridgebio.com (opens in a new tab)

BridgeBio growth playbook

Diagnosis

BridgeBio is moving from one main commercial medicine to a multi-product portfolio, and its hiring says so: HCP and community marketers for upcoming launches, eight field reimbursement managers, managed markets directors, omnichannel analytics, an international customer engagement lead and ADH1 disease education in Germany.

The site is strong on science but uneven where doctors act: ADH1 has a BridgeBio-run testing program, LGMD2I/R9 sends doctors elsewhere; a single sign-up treats every audience alike; and the testing hub still shows a summer tour.

This playbook starts with an LGMD2I/R9 testing path for doctors, audience-aware sign-up, an office access toolkit and site fixes, then builds clinic mapping, peer education, rare-disease KPIs, modular international content and a portfolio diagnosis service.

Growth Score

7/10

Biggest Opportunity

Make diagnosis the shared growth engine: easy testing for doctors in every condition finds the patients who wait years for an answer.

Biggest Risk

Several launches at once stretch small teams, while established medicines from larger companies compete for the same specialists.

01

Start here

The three moves to make first. Each one is written up in full below.

  1. 1

    Give neuromuscular doctors an LGMD2I/R9 testing path as easy as the one BridgeBio built for ADH1

    Put the ADH1 and LGMD2I/R9 HCP testing pages side by side and list what the LGMD page is missing.

    High impact First result in 1 month
  2. 2

    Replace the "Summer '26" testing tour panel with what it achieved and a way to request the next stop

    Change the panel heading and add the at-home kit link.

    Medium impact First result in 1 week
  3. 3

    Ask who is signing up: one audience and condition choice on the "Stay informed" form

    Add the two fields to the Marketo form.

    High impact First result in 1 month

02

Your idea portfolio

21 ideas, grouped by when to run them. Open any idea for how to run it: the steps, who to approach, copy you can use, and how to measure it.

  • 8 ideas are marked Unexpected: plays you are unlikely to have tried.

Every idea placed by the effort it takes against the impact it could have. Quick wins sit top left; select a number to open that idea. The filters below narrow the list by status, timing, category and what Programmable can build.

Effort vs impactEach number is an idea. Select one to open it.
Impact →
Quick wins · 2Big bets · 10Fill-ins · 5Reconsider · 4
Effort →

Showing 21 of 21 ideas

This week 6

Quick wins with a clear first action.

  • 01

    BridgeBio is hiring an HCP marketer to "identify doctors that have, or are most likely to have LGMD2I/R9 patients" and to evolve the disease education campaign. Its own site shows the gap: for ADH1, BridgeBio runs sponsored testing with a kit order form, prepaid return postage and on-demand mobile sample collection; for LGMD2I/R9, the HCP page says BridgeBio "does not directly provide a testing program" and sends doctors to two outside programs. In a condition where diagnosis can take 10+ years and genetic testing is the only way to confirm it, the testing step is where undiagnosed patients are found.

    High impactMedium effort First result in 1 month Associate Director

    First action

    Put the ADH1 and LGMD2I/R9 HCP testing pages side by side and list what the LGMD page is missing.

    How to measure it

    Testing-order clicks from the LGMD2I/R9 HCP page

    Now
    –
    Target
    3x baseline
    By
    90 days

    Steps

    1. 1

      Compare the two programs

      Kit ordering, mobile collection, eligibility, turnaround and support for ADH1 vs LGMD2I/R9.

      Associate Director, HCP Marketing 2 days

    2. 2

      Write the checklist

      When to suspect a genetic LGMD and order testing, from published guidance.

      Medical Affairs 2 weeks

    3. 3

      Rebuild the page

      One primary action, both programs side by side, plain eligibility.

      Digital Marketing team 2 weeks

    4. 4

      Assess a sponsored option

      Kit and mobile collection like DetectHypopara, under program rules.

      Healthcare Compliance 1 month

    5. 5

      Track orders

      Tagged links and program-reported totals, aggregated by clinic type only.

      Associate Director, Omnichannel Analytics 1 week

    6. 6

      Equip the field

      Leave-behind and QR link for clinic visits and speaker programs.

      Neuromuscular Account Manager 2 weeks

    7. 7

      Review monthly

      Orders, diagnostic yield and clinic coverage.

      Associate Director, HCP Marketing monthly

    First result
    1 month
    Cost
    Page build, medical review; testing sponsorship if approved
    Owner
    Associate Director, HCP Marketing

    Smallest test

    Send the rebuilt page to 20 neuromuscular clinics and count orders for a month.

    Why it works

    Rebuild the LGMD2I/R9 HCP testing page around one action: order a no-cost test. Add a short "when to suspect a genetic LGMD" checklist reviewed by Medical Affairs, one-click links into both sponsored programs with clear eligibility, and, with Compliance, evaluate a BridgeBio-sponsored kit and mobile-collection option like DetectHypopara. Promote the page to neuromuscular clinics through the field team, speaker programs and medical meetings, and measure tracked order clicks by clinic type. Keep it unbranded disease education.

    Every diagnosis made today helps patients and their doctors whatever happens next, and the testing page is the most useful thing a neuromuscular clinic can be sent. The same step shows the HCP team which clinics are actively testing, which is exactly the targeting question the new role is asked to answer.

    Ready to use

    ChecklistLGMD2I/R9 HCP testing page

    [ ] One headline action: order a no-cost genetic test
    [ ] When to suspect a genetic LGMD (Medical Affairs reviewed)
    [ ] Both sponsored programs, eligibility and turnaround side by side
    [ ] Option for kit or mobile collection (if approved)
    [ ] What to do after a result: genetic counseling, advocacy organizations
    [ ] Tracked links per channel
    [ ] Unbranded, HCP-only, reviewed by Compliance

    Risks and how to handle them

    • Testing program seen as an inducement

      Keep testing independent of any prescribing; follow Compliance rules for sponsored programs.

    • Partner programs change terms

      Review the links and eligibility every quarter.

    Evidence

    • HiringAssociate Director, HCP Marketing (San Francisco, posted September 11, 2026): will "lead the development and execution of tactics supporting the commercial launch of BBP-418"; "develop tactics that will help identify doctors that have, or are most likely to have LGMD2I/R9 patients"; "Manage and evolve the disease education campaign and educational resources"; run the speaker bureau and "the creation of all HCP peer-to-peer educational content"; "Develop targeted measurement plans".Source
    • Your websiteLGMD2I/R9 genetic testing page for healthcare professionals: "While BridgeBio does not directly provide a testing program for LGMD2I/R9 at this time, we are committed to helping you find the resources you need." It links out to two third-party sponsored programs (Detect Muscular Dystrophy and The Lantern Project), and notes that "cardiac and respiratory involvement is more common" than in other subtypes and that there are "over 30 identified LGMD subtypes".Source
    • Your websiteADH1 testing, by contrast, is BridgeBio-run: "DetectHypopara Sponsored Testing" with Prevention Genetics, an HCP test kit order form ("Kits will include pre-paid return postage") and an option to "Schedule an on-demand test", plus patient and HCP pages for ADH1 and hypoparathyroidism.Source
    • Your websiteLGMD2I/R9 condition page: "7,000+ estimated individuals living with LGMD2I/R9 in the U.S. and Europe"; "As many as 10+ years to receive diagnosis due to variability of symptoms"; "Genetic testing is the only way to confirm a diagnosis of LGMD2I/R9."Source
    • HiringLaunch field and access roles open now: a Neuromuscular Account Manager (Mid-Atlantic, posted October 23, 2026) with "subject matter expertise concerning scientific and clinical information for BBP-418"; a Commercial Learning & Development Associate Director as "training lead for the product launch"; a Regional Sales Director - Attruby; and Managed Markets directors (national and regional accounts) supporting "launch and post-launch strategies across the BBIO portfolio".Source
  • 02

    The genetic testing hub still advertises the "BridgeBio Genetic Testing Tour Summer '26" with west coast stops, in late October. A past-dated event at the top of a page about getting answers makes the whole program look inactive to a doctor or family arriving today.

    Medium impactLow effort First result in 1 week Digital Marketing team

    First action

    Change the panel heading and add the at-home kit link.

    How to measure it

    Kit and visit requests from the hub

    Now
    –
    Target
    +20%
    By
    60 days

    Steps

    1. 1

      Pull the tour totals

      Stops, visits and tests, aggregated.

      Patient Services 2 days

    2. 2

      Write the recap

      Two lines and a map.

      Digital Marketing team 1 day

    3. 3

      Add the request form

      Community requests for future stops.

      Digital Marketing team 2 days

    4. 4

      Lead with at-home testing

      The option available today.

      Digital Marketing team 1 hour

    5. 5

      Add expiry dates

      Event panels end automatically.

      Digital Marketing team 1 day

    6. 6

      Measure

      Requests per month.

      Associate Director, Omnichannel Analytics monthly

    First result
    1 week
    Cost
    Staff time only
    Owner
    Digital Marketing team

    Smallest test

    Update the panel copy today.

    Why it works

    Swap the panel for a short recap (cities visited, people tested, in aggregate) and a standing "request testing in your community" form, plus the at-home kit option that works any time. Add an end date to future event panels so they retire themselves.

    Fresh pages earn trust and keep the free testing offer, which is the real call to action, in front of visitors.

    Risks and how to handle them

    • Low tour numbers look weak

      Show the cities and the standing offer instead of totals.

    Evidence

    • Your websiteGenetic testing hub (checked October 23, 2026): rare disease patients "see an average of 7.3 physicians before receiving a correct diagnosis"; at-home and on-demand mobile testing; and a "BridgeBio Genetic Testing Tour Summer '26" panel listing west coast stops (Seattle to Phoenix) focused on ADH1 and hypoparathyroidism, still shown in late October with "We will be adding stops along the way".Source
    • Your websiteADH1 testing, by contrast, is BridgeBio-run: "DetectHypopara Sponsored Testing" with Prevention Genetics, an HCP test kit order form ("Kits will include pre-paid return postage") and an option to "Schedule an on-demand test", plus patient and HCP pages for ADH1 and hypoparathyroidism.Source
    • HiringDisease Network Specialist, Rare Endocrinology, EU Center (Germany, posted October 22, 2026): "improve the diagnosis rates of autosomal dominant hypocalcemia type 1 (ADH1)" with "a focus on disease education in the 2027 pre-launch phase"; share "guideline-aligned diagnostic algorithms"; support "the logistics of genetic testing, including family testing initiated by the treating physician". A Medical Science Liaison, a Market Access Manager and a Senior Director, Commercial are also being hired for the EU Center.Source
  • 03

    The site's only sign-up is a footer form with one checkbox, "I agree to receive updates from BridgeBio". Doctors, patients and caregivers, investors and job seekers all land in one list, which the new omnichannel analytics lead is meant to turn into measured, relevant journeys for small audiences.

    High impactLow effort First result in 1 month Associate Director

    First action

    Add the two fields to the Marketo form.

    How to measure it

    Share of sign-ups segmented

    Now
    –
    Target
    90%
    By
    60 days

    Steps

    1. 1

      Agree the streams

      Audiences, conditions and what each may receive.

      Associate Director, Omnichannel Analytics 1 week

    2. 2

      Compliance review

      Content rules per audience, especially for investigational programs.

      Healthcare Compliance 1 week

    3. 3

      Edit the form

      Two fields, same checkbox.

      Digital Marketing team 1 day

    4. 4

      Build streams

      Welcome emails per audience.

      Digital Marketing team 2 weeks

    5. 5

      Back-fill

      Ask current subscribers to choose.

      Digital Marketing team 1 week

    6. 6

      Report

      Growth by audience and condition.

      Associate Director, Omnichannel Analytics monthly

    First result
    1 month
    Cost
    Staff time only
    Owner
    Associate Director, Omnichannel Analytics

    Smallest test

    Add the "I am a" field this week.

    Why it works

    Add two fields: "I am a" (healthcare professional, patient or caregiver, advocate, investor, job seeker) and the conditions they care about. Route each to its own stream: HCPs to disease education and testing updates, patients and caregivers to community, testing and support updates (and approved-medicine information only where it applies), investors to the IR list. Report sign-ups by audience and condition.

    Small rare-disease audiences make every subscriber valuable; relevant streams raise opens and lower unsubscribes, and the condition choice shows where interest is growing.

    Risks and how to handle them

    • Patients receive promotional content for unapproved products

      Patient streams carry disease education, testing and support only.

    Evidence

    • Your websiteHomepage: "$8 billion peak year sales potential", "3 FDA approvals received" and "70+ published peer reviewed papers", with a footnote that Encaleret, BBP-418 and Infigratinib "have not yet received FDA or other regulatory approval"; links to the On Rare podcast and Insights; "This site is intended for U.S. residents." The only sign-up is a footer form, "Stay informed.", with one checkbox: "I agree to receive updates from BridgeBio" - no choice of audience or condition.Source
    • HiringAssociate Director, Omnichannel Analytics: "In the rare disease space - where audiences are small, journeys are complex, and impact is profound - this role is critical to ensuring that every interaction is meaningful, compliant, and effective"; measures websites, paid media, email/CRM, social and programmatic; attribution and mix modeling; "next-best-action".Source
    • HiringAssociate Director/Director Customer Engagement, International (Zug, posted October 13, 2026): owns "the International omnichannel customer engagement strategy across HCPs and patients", including "disease-awareness websites, HCP portals, email and marketing automation, and paid and organic social media"; sets "modular content requirements and localization guardrails"; pilots AI tools "in a compliant and measurable way". A Director, Sales Force Effectiveness, International was posted the same day.Source
  • 04

    Real visitors pass Core Web Vitals today, but the mobile lab test shows a 10.3 s largest paint and 21 MB of third-party downloads, almost all of it a homepage video, and the field largest paint is trending about 10% slower. Visitors on hospital Wi-Fi or a phone pay that cost before seeing anything.

    Medium impactLow effort First result in 1 week Digital Marketing team

    First action

    Replace the autoplay video with a poster image on mobile.

    How to measure it

    Mobile page weight

    Now
    –
    Target
    under 3 MB
    By
    30 days

    Steps

    1. 1

      Measure

      Current weight by device.

      Digital Marketing team 1 hour

    2. 2

      Poster first

      Image placeholder.

      Digital Marketing team 1 day

    3. 3

      Lazy-load the video

      Desktop or on tap only.

      Digital Marketing team 1 day

    4. 4

      Compress

      Web-sized encodes.

      Digital Marketing team 1 day

    5. 5

      Retest

      PageSpeed mobile.

      Digital Marketing team 1 hour

    6. 6

      Guard

      Weight check in releases.

      Digital Marketing team ongoing

    First result
    1 week
    Cost
    $0
    Owner
    Digital Marketing team

    Smallest test

    Turn off the mobile video for a week and compare.

    Why it works

    Serve a poster image first, load the video only on larger screens or on tap, compress it for the web, and check the page weight in the release checklist.

    A lighter homepage keeps the field numbers passing as traffic grows around launches and news.

    Risks and how to handle them

    • Brand film loses views

      Keep it one tap away.

    Evidence

    • Google PageSpeedHomepage on mobile: lab performance score 32, largest paint 10.3 s and 1.9 s of blocking time (desktop 77). Real Chrome visitors pass Core Web Vitals (largest paint 1.5 s, INP 136 ms, CLS 0.01), but field largest paint is trending about 10% slower. The page pulls about 21 MB from 24 third-party services; about 19.6 MB is video from the content CDN, and the tag manager blocks for about 2.1 s.Source
  • 05

    The homepage loads 24 third-party services, with the tag manager blocking the page for about 2.1 s on mobile. Several ad and measurement platforms overlap, and the omnichannel analytics lead will need to know which tags feed which reports.

    Medium impactMedium effort First result in 1 month Associate Director

    First action

    Export the tag manager container and list owners.

    How to measure it

    Mobile blocking time

    Now
    –
    Target
    under 600 ms
    By
    60 days

    Steps

    1. 1

      Inventory tags

      Owner, purpose, pages.

      Associate Director, Omnichannel Analytics 1 week

    2. 2

      Mark duplicates

      Overlapping ad and analytics tools.

      Associate Director, Omnichannel Analytics 2 days

    3. 3

      Remove unowned

      No owner, no tag.

      Digital Marketing team 1 week

    4. 4

      Defer the rest

      After consent and render.

      Digital Marketing team 1 week

    5. 5

      Document

      Which reports each tag feeds.

      Associate Director, Omnichannel Analytics 1 week

    6. 6

      Review quarterly

      New tags need an owner.

      Associate Director, Omnichannel Analytics quarterly

    First result
    1 month
    Cost
    Staff time only
    Owner
    Associate Director, Omnichannel Analytics

    Smallest test

    Remove one duplicate tag and remeasure.

    Why it works

    List every tag with its owner, purpose, pages and consent category; remove duplicates and tags with no owner; load the rest after consent and after the page renders; and document the measurement each tag supports.

    Fewer, owned tags make the site faster and the attribution the new team builds more trustworthy.

    Risks and how to handle them

    • Lost campaign data

      Check each removal with the campaign owner first.

    Evidence

    • Google PageSpeedHomepage on mobile: lab performance score 32, largest paint 10.3 s and 1.9 s of blocking time (desktop 77). Real Chrome visitors pass Core Web Vitals (largest paint 1.5 s, INP 136 ms, CLS 0.01), but field largest paint is trending about 10% slower. The page pulls about 21 MB from 24 third-party services; about 19.6 MB is video from the content CDN, and the tag manager blocks for about 2.1 s.Source
    • HiringAssociate Director, Omnichannel Analytics: "In the rare disease space - where audiences are small, journeys are complex, and impact is profound - this role is critical to ensuring that every interaction is meaningful, compliant, and effective"; measures websites, paid media, email/CRM, social and programmatic; attribution and mix modeling; "next-best-action".Source
  • 06

    BridgeBio is hiring eight Field Reimbursement Managers to teach provider offices "benefits investigation, prior authorization, appeals, and coverage pathways" across a rare disease portfolio. The public Access page covers patients after a prescription, but there is no page for office staff who do the paperwork.

    High impactLow effort First result in 1 month Field Reimbursement Manager

    First action

    Interview two FRMs on the questions offices ask most.

    How to measure it

    Median days to first fill

    Now
    –
    Target
    -20%
    By
    2 quarters

    Steps

    1. 1

      Collect questions

      Top office questions.

      Field Reimbursement Manager 1 week

    2. 2

      Draft the toolkit

      Checklists and contacts.

      Patient Services 2 weeks

    3. 3

      Review

      Medical, Legal, Compliance.

      Healthcare Compliance 2 weeks

    4. 4

      Publish

      HCP-only office page.

      Digital Marketing team 1 week

    5. 5

      Train FRMs

      Use it on every visit.

      Associate Director, Commercial Learning & Development 1 week

    6. 6

      Measure

      Days to fill and toolkit visits.

      Associate Director, Omnichannel Analytics monthly

    First result
    1 month
    Cost
    Staff time only
    Owner
    Field Reimbursement Manager

    Smallest test

    Share a one-page checklist with ten offices.

    Why it works

    Publish an office-staff access page for Attruby, the approved medicine, today: steps from prescription to first fill, prior authorization and appeal checklists, the ForgingBridges hub contact, and how to reach the regional FRM. Build it as a template the portfolio can reuse after any future approvals.

    Office staff decide how fast a prescription becomes a delivered medicine; a clear toolkit multiplies each FRM's reach between visits.

    Risks and how to handle them

    • Payer rules change

      Date the page and review monthly.

    Evidence

    • HiringEight regional Field Reimbursement Manager posts (Atlantic, Great Lakes, Michigan, Northeast, Northern CA, Pacific, Pennsylvania, Southeast; posted October 16-19, 2026), "responsible for executing the launch strategy across a rare disease portfolio": educating provider offices on "benefits investigation, prior authorization, appeals, and coverage pathways" and coordinating "hubs, specialty pharmacies, prescriber offices, and support programs".Source
    • Your websitePatients section: the Stories hub lists three stories (people living with hypochondroplasia, ADH1 and LGMD2I/R9); the Support page lists advocacy organizations per condition (for example Little People of America, CureLGMD2i Foundation, HypoPARAthyroidism Association); the Access page offers ForgingBridges Patient Access Liaisons "post-prescription". The achondroplasia page links to the family site MyAchonJourney.com.Source
    • Press releaseFull year 2025 results (February 24, 2026): $502.1 million in revenue; Attruby had "7,804 unique patient prescriptions written by 1,856 unique prescribers as of February 20, 2026"; the CEO said "we hope this leads to 6 approved products as our first decade draws to a close".Source

This quarter 10

The core plays for the next three months.

  • 07

    The HCP marketer must find doctors most likely to see LGMD2I/R9, a condition with about 7,000 people estimated across the U.S. and Europe. Claims data alone misses patients who are undiagnosed or coded as generic muscular dystrophy.

    High impactMedium effort First result in 1 quarter Associate Director

    First action

    List every public LGMD trial site in the U.S.

    How to measure it

    Priority clinics engaged

    Now
    –
    Target
    80%
    By
    2 quarters

    Steps

    1. 1

      Collect sources

      Trial registries, care networks, publications.

      Associate Director, Omnichannel Analytics 2 weeks

    2. 2

      Score clinics

      Likelihood of LGMD patients.

      Associate Director, Omnichannel Analytics 2 weeks

    3. 3

      Validate

      With MSLs and field teams.

      Medical Affairs 2 weeks

    4. 4

      Assign

      To territories.

      Director of Commercial Excellence 1 week

    5. 5

      Engage

      Disease education and testing page.

      Neuromuscular Account Manager ongoing

    6. 6

      Refresh

      Quarterly.

      Associate Director, Omnichannel Analytics quarterly

    First result
    1 quarter
    Cost
    Analyst time
    Owner
    Associate Director, Omnichannel Analytics

    Smallest test

    Score the top 50 clinics by hand.

    Why it works

    Build a clinic list from public sources: BridgeBio and other LGMD trial sites, neuromuscular care center networks, authors of FKRP and LGMD publications, and genetic testing program volumes in aggregate. Score clinics, share the list with field and medical teams, and refresh quarterly.

    In ultra-rare disease a few clinics see most patients; finding them early focuses the whole launch team.

    Risks and how to handle them

    • Privacy concerns

      Use clinic-level public data only.

    Evidence

    • HiringAssociate Director, HCP Marketing (San Francisco, posted September 11, 2026): will "lead the development and execution of tactics supporting the commercial launch of BBP-418"; "develop tactics that will help identify doctors that have, or are most likely to have LGMD2I/R9 patients"; "Manage and evolve the disease education campaign and educational resources"; run the speaker bureau and "the creation of all HCP peer-to-peer educational content"; "Develop targeted measurement plans".Source
    • Your websiteLGMD2I/R9 condition page: "7,000+ estimated individuals living with LGMD2I/R9 in the U.S. and Europe"; "As many as 10+ years to receive diagnosis due to variability of symptoms"; "Genetic testing is the only way to confirm a diagnosis of LGMD2I/R9."Source
    • HiringAssociate Director, Omnichannel Analytics: "In the rare disease space - where audiences are small, journeys are complex, and impact is profound - this role is critical to ensuring that every interaction is meaningful, compliant, and effective"; measures websites, paid media, email/CRM, social and programmatic; attribution and mix modeling; "next-best-action".Source
    • Your websiteLGMD2I/R9 genetic testing page for healthcare professionals: "While BridgeBio does not directly provide a testing program for LGMD2I/R9 at this time, we are committed to helping you find the resources you need." It links out to two third-party sponsored programs (Detect Muscular Dystrophy and The Lantern Project), and notes that "cardiac and respiratory involvement is more common" than in other subtypes and that there are "over 30 identified LGMD subtypes".Source
  • 08

    The HCP marketer will run the speaker bureau and "all HCP peer-to-peer educational content". Live programs reach the doctors in the room; most neuromuscular and endocrine doctors who see one patient in years will never attend.

    High impactMedium effort First result in 1 quarter Associate Director

    First action

    Record the next disease-education program.

    How to measure it

    Module completions

    Now
    –
    Target
    1,000
    By
    2 quarters

    Steps

    1. 1

      Plan topics

      Three modules per condition.

      Associate Director, HCP Marketing 2 weeks

    2. 2

      Review

      Medical and Compliance.

      Healthcare Compliance 1 month

    3. 3

      Record

      Next programs.

      Associate Director, HCP Marketing ongoing

    4. 4

      Publish

      HCP-only library.

      Digital Marketing team 1 month

    5. 5

      Promote

      Email and field.

      Neuromuscular Account Manager ongoing

    6. 6

      Measure

      Completions and testing clicks.

      Associate Director, Omnichannel Analytics monthly

    First result
    1 quarter
    Cost
    Production costs
    Owner
    Associate Director, HCP Marketing

    Smallest test

    Publish one module and email it to clinics.

    Why it works

    Record approved disease-education programs, cut them into 10-minute modules (recognising the disease, ordering a test, multidisciplinary care), and publish them in an HCP-only library with email follow-up.

    On-demand content reaches the long tail of doctors who see a rare patient once and need help that day.

    Risks and how to handle them

    • Off-label discussion

      Use only approved disease-education content.

    Evidence

    • HiringAssociate Director, HCP Marketing (San Francisco, posted September 11, 2026): will "lead the development and execution of tactics supporting the commercial launch of BBP-418"; "develop tactics that will help identify doctors that have, or are most likely to have LGMD2I/R9 patients"; "Manage and evolve the disease education campaign and educational resources"; run the speaker bureau and "the creation of all HCP peer-to-peer educational content"; "Develop targeted measurement plans".Source
    • Your websiteSitemap (142 URLs, October 23, 2026): 100 under /science (condition, research, presentation and testing pages), 15 Insights posts (including "The genetic testing gap" and "What makes a drug launch successful"), 7 patient pages and 3 EU pages.Source
    • Your websiteLGMD2I/R9 genetic testing page for healthcare professionals: "While BridgeBio does not directly provide a testing program for LGMD2I/R9 at this time, we are committed to helping you find the resources you need." It links out to two third-party sponsored programs (Detect Muscular Dystrophy and The Lantern Project), and notes that "cardiac and respiratory involvement is more common" than in other subtypes and that there are "over 30 identified LGMD subtypes".Source
  • 09

    The Stories hub lists three stories, none from the ATTR-CM community, where Attruby, BridgeBio's main approved medicine, already had 7,804 patient prescriptions by February. Stories are what patients, doctors and journalists remember.

    Medium impactMedium effort First result in 1 quarter VP Global Media Relations & E…

    First action

    Ask two advocacy partners for families willing to share.

    How to measure it

    Stories in the hub

    Now
    –
    Target
    12
    By
    1 year

    Steps

    1. 1

      Plan

      One per month across conditions.

      VP Global Media Relations & Executive Communications 2 weeks

    2. 2

      Find storytellers

      Through advocacy partners.

      Patient Advocacy ongoing

    3. 3

      Consent and review

      Legal and Compliance.

      Healthcare Compliance ongoing

    4. 4

      Produce

      Text, photo and short video.

      VP Global Media Relations & Executive Communications monthly

    5. 5

      Share

      Social, podcast, newsletter.

      Digital Marketing team monthly

    6. 6

      Measure

      Views and shares.

      Associate Director, Omnichannel Analytics monthly

    First result
    1 quarter
    Cost
    Production costs
    Owner
    VP Global Media Relations & Executive Communications

    Smallest test

    Publish one ATTR-CM caregiver story.

    Why it works

    With consent and advocacy partners, add a story per month: ATTR-CM patients and caregivers, families living with achondroplasia, ADH1 and LGMD2I/R9, and doctors on the diagnosis journey. Keep stories about lived experience; route any product discussion to approved materials.

    Human stories earn press and social reach, and they support the new media relations lead's single narrative.

    Risks and how to handle them

    • Stories read as promotion

      Focus on lived experience, not medicine claims.

    Evidence

    • Your websitePatients section: the Stories hub lists three stories (people living with hypochondroplasia, ADH1 and LGMD2I/R9); the Support page lists advocacy organizations per condition (for example Little People of America, CureLGMD2i Foundation, HypoPARAthyroidism Association); the Access page offers ForgingBridges Patient Access Liaisons "post-prescription". The achondroplasia page links to the family site MyAchonJourney.com.Source
    • Press releaseFull year 2025 results (February 24, 2026): $502.1 million in revenue; Attruby had "7,804 unique patient prescriptions written by 1,856 unique prescribers as of February 20, 2026"; the CEO said "we hope this leads to 6 approved products as our first decade draws to a close".Source
    • HiringExecutive Director/VP Global Media Relations, Executive Communications & Comm Ops (posted October 13, 2026): "setting one coherent corporate narrative and adapting it across every market"; leads media around "clinical data readouts, regulatory milestones, earnings, and business development announcements".Source
  • 10

    The new international customer engagement lead must set "modular content requirements and localization guardrails" across disease-awareness websites and HCP portals. BridgeBio.com is "intended for U.S. residents" and has just three EU pages, while the EU Center is hiring for ADH1 disease education ahead of 2027.

    High impactHigh effort First result in 2 quarters Director

    First action

    Break the ADH1 HCP page into modules.

    How to measure it

    Days to publish a localized page

    Now
    –
    Target
    -50%
    By
    2 quarters

    Steps

    1. 1

      Define modules

      Claim, reference, asset.

      Director, Customer Engagement, International 1 month

    2. 2

      Tag U.S. content

      Condition and testing pages.

      Digital Marketing team 1 month

    3. 3

      Set guardrails

      What may change locally.

      Healthcare Compliance 2 weeks

    4. 4

      Pilot Germany

      ADH1 HCP pages.

      Disease Network Specialist, Rare Endocrinology, EU Center 1 month

    5. 5

      Measure

      Review time and use.

      Associate Director, Omnichannel Analytics monthly

    6. 6

      Scale

      Next markets.

      Director, Customer Engagement, International quarterly

    First result
    2 quarters
    Cost
    Content system costs
    Owner
    Director, Customer Engagement, International

    Smallest test

    Localize one ADH1 module into German.

    Why it works

    Break the U.S. condition, testing and glossary pages into approved modules (claim, reference, image), store them once, and assemble local versions per country with local review. Start with ADH1 for Germany.

    Modular content cuts review time and keeps science consistent across markets with small teams.

    Risks and how to handle them

    • Local rules differ

      Local review on every page.

    Evidence

    • HiringAssociate Director/Director Customer Engagement, International (Zug, posted October 13, 2026): owns "the International omnichannel customer engagement strategy across HCPs and patients", including "disease-awareness websites, HCP portals, email and marketing automation, and paid and organic social media"; sets "modular content requirements and localization guardrails"; pilots AI tools "in a compliant and measurable way". A Director, Sales Force Effectiveness, International was posted the same day.Source
    • Your websiteHomepage: "$8 billion peak year sales potential", "3 FDA approvals received" and "70+ published peer reviewed papers", with a footnote that Encaleret, BBP-418 and Infigratinib "have not yet received FDA or other regulatory approval"; links to the On Rare podcast and Insights; "This site is intended for U.S. residents." The only sign-up is a footer form, "Stay informed.", with one checkbox: "I agree to receive updates from BridgeBio" - no choice of audience or condition.Source
    • Your websiteSitemap (142 URLs, October 23, 2026): 100 under /science (condition, research, presentation and testing pages), 15 Insights posts (including "The genetic testing gap" and "What makes a drug launch successful"), 7 patient pages and 3 EU pages.Source
    • HiringDisease Network Specialist, Rare Endocrinology, EU Center (Germany, posted October 22, 2026): "improve the diagnosis rates of autosomal dominant hypocalcemia type 1 (ADH1)" with "a focus on disease education in the 2027 pre-launch phase"; share "guideline-aligned diagnostic algorithms"; support "the logistics of genetic testing, including family testing initiated by the treating physician". A Medical Science Liaison, a Market Access Manager and a Senior Director, Commercial are also being hired for the EU Center.Source
  • 11

    The EU Center's new disease network specialist is asked to raise ADH1 diagnosis rates by sharing diagnostic algorithms and supporting genetic testing, including family testing. The U.S. site has a full ADH1 testing program; there is no German-language equivalent for endocrinologists.

    High impactMedium effort First result in 2 quarters Disease Network Specialist

    First action

    Translate the ADH1 HCP algorithm.

    How to measure it

    Testing requests from Germany

    Now
    –
    Target
    50
    By
    2 quarters

    Steps

    1. 1

      Translate

      Algorithm and testing steps.

      Disease Network Specialist, Rare Endocrinology, EU Center 2 weeks

    2. 2

      Local review

      Medical and compliance (HWG).

      Medical Affairs 1 month

    3. 3

      Arrange testing route

      Local lab partner.

      Market Access Manager, EU Center 1 month

    4. 4

      Publish

      HCP-only page.

      Digital Marketing team 1 week

    5. 5

      Equip the field

      Short link and QR.

      Disease Network Specialist, Rare Endocrinology, EU Center 1 week

    6. 6

      Measure

      Visits and requests.

      Associate Director, Omnichannel Analytics monthly

    First result
    2 quarters
    Cost
    Translation and review
    Owner
    Disease Network Specialist, Rare Endocrinology, EU Center

    Smallest test

    Share the translated algorithm with five centers.

    Why it works

    Publish a German HCP page with the guideline-aligned algorithm, when to suspect a genetic cause of hypoparathyroidism, how to arrange testing, and family testing guidance, reviewed locally. Give the specialist a short link and QR for clinic visits.

    Field specialists cover more centers when each visit ends with a resource doctors can use later.

    Risks and how to handle them

    • Promotion of an unapproved medicine

      Keep to disease education and testing.

    Evidence

    • HiringDisease Network Specialist, Rare Endocrinology, EU Center (Germany, posted October 22, 2026): "improve the diagnosis rates of autosomal dominant hypocalcemia type 1 (ADH1)" with "a focus on disease education in the 2027 pre-launch phase"; share "guideline-aligned diagnostic algorithms"; support "the logistics of genetic testing, including family testing initiated by the treating physician". A Medical Science Liaison, a Market Access Manager and a Senior Director, Commercial are also being hired for the EU Center.Source
    • Your websiteADH1 testing, by contrast, is BridgeBio-run: "DetectHypopara Sponsored Testing" with Prevention Genetics, an HCP test kit order form ("Kits will include pre-paid return postage") and an option to "Schedule an on-demand test", plus patient and HCP pages for ADH1 and hypoparathyroidism.Source
    • HiringAssociate Director/Director Customer Engagement, International (Zug, posted October 13, 2026): owns "the International omnichannel customer engagement strategy across HCPs and patients", including "disease-awareness websites, HCP portals, email and marketing automation, and paid and organic social media"; sets "modular content requirements and localization guardrails"; pilots AI tools "in a compliant and measurable way". A Director, Sales Force Effectiveness, International was posted the same day.Source
  • 12

    The achondroplasia community marketing director is asked to "identify and develop community members for ambassador programming" and to "uncover and address unmet community needs". The community holds a wide range of views on treatment, and BridgeBio's own page says families tailor choices to what feels right for them.

    High impactMedium effort First result in 1 quarter Director

    First action

    Ask two advocacy partners to co-host the first panel.

    How to measure it

    Materials reviewed by the panel

    Now
    –
    Target
    100%
    By
    2 quarters

    Steps

    1. 1

      Design the panel

      Size, pay, scope.

      Director, Marketing - Achondroplasia Community 2 weeks

    2. 2

      Recruit

      With advocacy partners.

      Patient Advocacy 1 month

    3. 3

      Meet

      Quarterly reviews.

      Director, Marketing - Achondroplasia Community quarterly

    4. 4

      Apply changes

      Language and imagery.

      Director, Marketing - Achondroplasia Community ongoing

    5. 5

      Report back

      What changed.

      Director, Marketing - Achondroplasia Community quarterly

    6. 6

      Design ambassadors

      After two sessions.

      Director, Marketing - Achondroplasia Community 1 quarter

    First result
    1 quarter
    Cost
    Panel honoraria
    Owner
    Director, Marketing Achondroplasia Community

    Smallest test

    Hold one listening session.

    Why it works

    Form a paid advisory panel of adults living with achondroplasia and parents, recruited with advocacy groups such as Little People of America, to review language, imagery and education before anything public. Publish what the panel changed. Only then design ambassador roles, with clear rules on what ambassadors discuss.

    Respect earns trust in a community that is wary of being told it needs fixing, and the panel prevents costly missteps.

    Risks and how to handle them

    • Seen as recruitment for a product

      Keep the panel about community needs and education.

    Evidence

    • HiringDirector, Marketing - Achondroplasia Community (open since April 2026): supports the planned commercial launch of infigratinib; "Identify and develop community members for ambassador programming"; "Uncover and address unmet community needs by seeking insights"; "Coordinate with digital marketing to build an effective customer engagement ecosystem"; "Partner closely with advocacy teams".Source
    • Your websitePatients section: the Stories hub lists three stories (people living with hypochondroplasia, ADH1 and LGMD2I/R9); the Support page lists advocacy organizations per condition (for example Little People of America, CureLGMD2i Foundation, HypoPARAthyroidism Association); the Access page offers ForgingBridges Patient Access Liaisons "post-prescription". The achondroplasia page links to the family site MyAchonJourney.com.Source
  • 13

    The omnichannel analytics lead is hired for audiences that "are small" and "journeys are complex". Standard media KPIs (impressions, clicks) say little when a condition has a few thousand patients.

    High impactMedium effort First result in 1 quarter Associate Director

    First action

    Draft five KPIs for LGMD2I/R9.

    How to measure it

    Teams reviewing the dashboard monthly

    Now
    –
    Target
    3
    By
    1 quarter

    Steps

    1. 1

      Draft KPIs

      Per condition.

      Associate Director, Omnichannel Analytics 2 weeks

    2. 2

      Agree

      Marketing, field, medical.

      Director of Commercial Excellence 2 weeks

    3. 3

      Connect data

      Testing, CRM, web.

      Associate Director, Omnichannel Analytics 1 month

    4. 4

      Build dashboard

      One view.

      Associate Director, Omnichannel Analytics 1 month

    5. 5

      Review

      Monthly.

      Director of Commercial Excellence monthly

    6. 6

      Shift budget

      Toward what finds patients.

      Associate Director, HCP Marketing quarterly

    First result
    1 quarter
    Cost
    Analyst time
    Owner
    Associate Director, Omnichannel Analytics

    Smallest test

    Report one condition's KPIs by hand.

    Why it works

    Define rare-disease KPIs per condition: clinics reached, tests ordered, diagnosed patients connected to support, time to diagnosis. Build one dashboard for marketing, field and medical teams.

    The right measures move budget to what finds patients, which is the outcome that matters.

    Risks and how to handle them

    • Data privacy

      Aggregate and follow program rules.

    Evidence

    • HiringAssociate Director, Omnichannel Analytics: "In the rare disease space - where audiences are small, journeys are complex, and impact is profound - this role is critical to ensuring that every interaction is meaningful, compliant, and effective"; measures websites, paid media, email/CRM, social and programmatic; attribution and mix modeling; "next-best-action".Source
    • HiringAssociate Director, HCP Marketing (San Francisco, posted September 11, 2026): will "lead the development and execution of tactics supporting the commercial launch of BBP-418"; "develop tactics that will help identify doctors that have, or are most likely to have LGMD2I/R9 patients"; "Manage and evolve the disease education campaign and educational resources"; run the speaker bureau and "the creation of all HCP peer-to-peer educational content"; "Develop targeted measurement plans".Source
    • Your websiteLGMD2I/R9 condition page: "7,000+ estimated individuals living with LGMD2I/R9 in the U.S. and Europe"; "As many as 10+ years to receive diagnosis due to variability of symptoms"; "Genetic testing is the only way to confirm a diagnosis of LGMD2I/R9."Source
  • 14

    BridgeBio is hiring eight FRMs and national and regional managed markets directors at once, and the FRM role asks them to "share payer policy trends and field insights". Without a shared view, each team learns the same payer issue separately.

    Medium impactMedium effort First result in 1 quarter Director

    First action

    Define five fields for each payer insight.

    How to measure it

    Median days to resolve a payer issue

    Now
    –
    Target
    -30%
    By
    2 quarters

    Steps

    1. 1

      Define fields

      Plan, issue, region, fix.

      Director, Managed Markets - National Accounts 1 week

    2. 2

      Set up the log

      In CRM.

      Senior Manager, Sales Operations 2 weeks

    3. 3

      Train FRMs

      Weekly entries.

      Associate Director, Commercial Learning & Development 1 week

    4. 4

      Review weekly

      Managed markets.

      Director, Managed Markets - National Accounts weekly

    5. 5

      Share

      With sales leaders.

      Regional Sales Director - Attruby weekly

    6. 6

      Measure

      Resolution time.

      Associate Director, Omnichannel Analytics monthly

    First result
    1 quarter
    Cost
    Staff time only
    Owner
    Director, Managed Markets National Accounts

    Smallest test

    Run the log for one region for a month.

    Why it works

    Create a weekly payer-insight log: denials, policy changes and fixes by plan and region, reviewed by managed markets and shared with sales leaders.

    Faster fixes to access issues shorten time to therapy, and patterns guide contract talks.

    Risks and how to handle them

    • Patient data in notes

      Plan-level entries only.

    Evidence

    • HiringEight regional Field Reimbursement Manager posts (Atlantic, Great Lakes, Michigan, Northeast, Northern CA, Pacific, Pennsylvania, Southeast; posted October 16-19, 2026), "responsible for executing the launch strategy across a rare disease portfolio": educating provider offices on "benefits investigation, prior authorization, appeals, and coverage pathways" and coordinating "hubs, specialty pharmacies, prescriber offices, and support programs".Source
    • HiringLaunch field and access roles open now: a Neuromuscular Account Manager (Mid-Atlantic, posted October 23, 2026) with "subject matter expertise concerning scientific and clinical information for BBP-418"; a Commercial Learning & Development Associate Director as "training lead for the product launch"; a Regional Sales Director - Attruby; and Managed Markets directors (national and regional accounts) supporting "launch and post-launch strategies across the BBIO portfolio".Source
  • 15

    BridgeBio already wrote about "The genetic testing gap" and runs sponsored ADH1 testing; its hub cites 7.3 physicians before diagnosis. Aggregate testing results (how many people tested, how many diagnosed, time to answer) would be original data on a known problem.

    Medium impactMedium effort First result in 2 quarters VP Global Media Relations & E…

    First action

    Ask the testing partner which aggregate numbers can be shared.

    How to measure it

    Articles citing the data

    Now
    –
    Target
    10
    By
    1 year

    Steps

    1. 1

      Agree data

      With testing partners.

      Medical Affairs 1 month

    2. 2

      Privacy review

      De-identified and aggregated.

      Healthcare Compliance 1 month

    3. 3

      Write

      Insight post and chart.

      VP Global Media Relations & Executive Communications 2 weeks

    4. 4

      Pitch

      Medical and trade press.

      VP Global Media Relations & Executive Communications 2 weeks

    5. 5

      Share

      LinkedIn and podcast.

      Digital Marketing team 1 week

    6. 6

      Repeat

      Twice a year.

      VP Global Media Relations & Executive Communications 6 months

    First result
    2 quarters
    Cost
    Staff time only
    Owner
    VP Global Media Relations & Executive Communications

    Smallest test

    Publish one aggregate chart.

    Why it works

    Twice a year, publish aggregated, de-identified results from sponsored testing programs with partner labs, alongside a doctor's commentary, and pitch it to medical and trade press.

    Original data earns coverage and links and positions BridgeBio as the company closing the diagnosis gap.

    Risks and how to handle them

    • Small numbers identify people

      Suppress small counts.

    Evidence

    • Your websiteSitemap (142 URLs, October 23, 2026): 100 under /science (condition, research, presentation and testing pages), 15 Insights posts (including "The genetic testing gap" and "What makes a drug launch successful"), 7 patient pages and 3 EU pages.Source
    • Your websiteGenetic testing hub (checked October 23, 2026): rare disease patients "see an average of 7.3 physicians before receiving a correct diagnosis"; at-home and on-demand mobile testing; and a "BridgeBio Genetic Testing Tour Summer '26" panel listing west coast stops (Seattle to Phoenix) focused on ADH1 and hypoparathyroidism, still shown in late October with "We will be adding stops along the way".Source
    • Your websiteADH1 testing, by contrast, is BridgeBio-run: "DetectHypopara Sponsored Testing" with Prevention Genetics, an HCP test kit order form ("Kits will include pre-paid return postage") and an option to "Schedule an on-demand test", plus patient and HCP pages for ADH1 and hypoparathyroidism.Source
    • HiringExecutive Director/VP Global Media Relations, Executive Communications & Comm Ops (posted October 13, 2026): "setting one coherent corporate narrative and adapting it across every market"; leads media around "clinical data readouts, regulatory milestones, earnings, and business development announcements".Source
  • 16

    BridgeBio runs the On Rare podcast and posts on LinkedIn, Instagram, YouTube and TikTok. Long episodes reach existing listeners; short clips reach the advocates, doctors and families who do not know the show yet.

    Medium impactLow effort First result in 1 month VP Global Media Relations & E…

    First action

    Cut three clips from the latest episode.

    How to measure it

    Monthly clip views

    Now
    –
    Target
    +50%
    By
    2 quarters

    Steps

    1. 1

      Pick moments

      Three per episode.

      VP Global Media Relations & Executive Communications monthly

    2. 2

      Edit

      Captions and formats.

      Digital Marketing team monthly

    3. 3

      Review

      Compliance.

      Healthcare Compliance monthly

    4. 4

      Post

      Each channel.

      Digital Marketing team monthly

    5. 5

      Link

      Episode and condition page.

      Digital Marketing team monthly

    6. 6

      Measure

      Views and listens.

      Associate Director, Omnichannel Analytics monthly

    First result
    1 month
    Cost
    Editing time
    Owner
    VP Global Media Relations & Executive Communications

    Smallest test

    Post clips from one episode.

    Why it works

    From each episode, cut three clips: one for the community, one for doctors on diagnosis, one for LinkedIn. Link each to the episode and the relevant condition page.

    Clips extend the life of content already made and send traffic to education pages.

    Risks and how to handle them

    • Out-of-context quotes

      Guest approval for clips.

    Evidence

    • Your websiteHomepage: "$8 billion peak year sales potential", "3 FDA approvals received" and "70+ published peer reviewed papers", with a footnote that Encaleret, BBP-418 and Infigratinib "have not yet received FDA or other regulatory approval"; links to the On Rare podcast and Insights; "This site is intended for U.S. residents." The only sign-up is a footer form, "Stay informed.", with one checkbox: "I agree to receive updates from BridgeBio" - no choice of audience or condition.Source
    • Your websitePatients section: the Stories hub lists three stories (people living with hypochondroplasia, ADH1 and LGMD2I/R9); the Support page lists advocacy organizations per condition (for example Little People of America, CureLGMD2i Foundation, HypoPARAthyroidism Association); the Access page offers ForgingBridges Patient Access Liaisons "post-prescription". The achondroplasia page links to the family site MyAchonJourney.com.Source

Big bets 3

Larger plays that can change the trajectory.

  • 17

    BridgeBio's testing support varies by condition: a BridgeBio-run ADH1 program with kits and mobile collection, links out for LGMD2I/R9. With several medicines heading for decisions and a hope of six approved products, diagnosis is a shared need across the hub-and-spoke model.

    High impactHigh effort First result in 3 quarters Senior Director

    First action

    Map today's testing options by condition.

    How to measure it

    Tests ordered

    Now
    –
    Target
    2x
    By
    1 year

    Steps

    1. 1

      Map options

      By condition.

      Senior Director, GTM Strategy & Portfolio Planning 1 month

    2. 2

      Design the service

      One flow.

      Senior Director, GTM Strategy & Portfolio Planning 1 quarter

    3. 3

      Partner labs

      Contracts.

      Market Access 1 quarter

    4. 4

      Compliance

      Program rules.

      Healthcare Compliance 1 quarter

    5. 5

      Launch

      HCP site.

      Digital Marketing team 1 month

    6. 6

      Measure

      Orders and yield.

      Associate Director, Omnichannel Analytics monthly

    First result
    3 quarters
    Cost
    Lab sponsorship costs
    Owner
    Senior Director, GTM Strategy & Portfolio Planning

    Smallest test

    Pilot one order flow for two conditions.

    Why it works

    Build one testing service for doctors: a single order flow for every supported condition, consistent kits and mobile collection, results support and genetic counseling, run centrally and used by each condition team.

    Central services are what the hub-and-spoke model is for, and a single front door is easier for doctors to remember and use.

    Risks and how to handle them

    • Program cost

      Prioritize conditions with the longest diagnosis delays.

    Evidence

    • Your websiteADH1 testing, by contrast, is BridgeBio-run: "DetectHypopara Sponsored Testing" with Prevention Genetics, an HCP test kit order form ("Kits will include pre-paid return postage") and an option to "Schedule an on-demand test", plus patient and HCP pages for ADH1 and hypoparathyroidism.Source
    • Your websiteLGMD2I/R9 genetic testing page for healthcare professionals: "While BridgeBio does not directly provide a testing program for LGMD2I/R9 at this time, we are committed to helping you find the resources you need." It links out to two third-party sponsored programs (Detect Muscular Dystrophy and The Lantern Project), and notes that "cardiac and respiratory involvement is more common" than in other subtypes and that there are "over 30 identified LGMD subtypes".Source
    • Press releaseFull year 2025 results (February 24, 2026): $502.1 million in revenue; Attruby had "7,804 unique patient prescriptions written by 1,856 unique prescribers as of February 20, 2026"; the CEO said "we hope this leads to 6 approved products as our first decade draws to a close".Source
    • Press releaseBridgeBio submitted the NDA for investigational oral BBP-418 in LGMD2I/R9 on March 30, 2026 and the FDA accepted it for priority review; the company anticipates a U.S. launch "following FDA approval in late 2026/early 2027". NDAs for infigratinib (achondroplasia) and encaleret (ADH1) have also been submitted and are under FDA review.Source
  • 18

    BridgeBio is hiring training, field, access and marketing roles for several launches at once and has published "What makes a drug launch successful". The hub can make each launch faster by reusing what worked.

    High impactHigh effort First result in 1 year Director of Commercial Excell…

    First action

    List the ten Attruby launch assets reused most.

    How to measure it

    Weeks to launch readiness

    Now
    –
    Target
    -25%
    By
    1 year

    Steps

    1. 1

      Inventory assets

      From Attruby.

      Director of Commercial Excellence 1 month

    2. 2

      Package

      Kit structure.

      Director of Commercial Excellence 1 month

    3. 3

      Train

      Teams on the kit.

      Associate Director, Commercial Learning & Development 1 quarter

    4. 4

      Use

      Next launch.

      Director of Commercial Excellence ongoing

    5. 5

      Review

      After each launch.

      Director of Commercial Excellence per launch

    6. 6

      Update

      Kit versions.

      Director of Commercial Excellence per launch

    First result
    1 year
    Cost
    Staff time only
    Owner
    Director of Commercial Excellence

    Smallest test

    Document one reusable asset.

    Why it works

    Package the Attruby launch's working parts (training curriculum, access toolkit, KPIs, content modules, field playbooks) as a launch kit owned by Commercial Excellence, and update it after each launch.

    Repeatable launches are the hub-and-spoke promise, and a kit lets small teams move fast.

    Risks and how to handle them

    • One size does not fit

      Kit as starting point, not rulebook.

    Evidence

    • HiringLaunch field and access roles open now: a Neuromuscular Account Manager (Mid-Atlantic, posted October 23, 2026) with "subject matter expertise concerning scientific and clinical information for BBP-418"; a Commercial Learning & Development Associate Director as "training lead for the product launch"; a Regional Sales Director - Attruby; and Managed Markets directors (national and regional accounts) supporting "launch and post-launch strategies across the BBIO portfolio".Source
    • HiringEight regional Field Reimbursement Manager posts (Atlantic, Great Lakes, Michigan, Northeast, Northern CA, Pacific, Pennsylvania, Southeast; posted October 16-19, 2026), "responsible for executing the launch strategy across a rare disease portfolio": educating provider offices on "benefits investigation, prior authorization, appeals, and coverage pathways" and coordinating "hubs, specialty pharmacies, prescriber offices, and support programs".Source
    • Your websiteSitemap (142 URLs, October 23, 2026): 100 under /science (condition, research, presentation and testing pages), 15 Insights posts (including "The genetic testing gap" and "What makes a drug launch successful"), 7 patient pages and 3 EU pages.Source
  • 19

    BridgeBio is building international teams in Zug, Paris and Germany, but bridgebio.com is "intended for U.S. residents" and has three EU pages. The customer engagement lead owns "HCP portals" and disease-awareness websites.

    High impactHigh effort First result in 1 year Director

    First action

    Pick the first two countries.

    How to measure it

    Registered HCPs

    Now
    –
    Target
    500
    By
    1 year

    Steps

    1. 1

      Pick countries

      Launch order.

      Director, Customer Engagement, International 1 month

    2. 2

      Build

      From modules.

      Digital Marketing team 1 quarter

    3. 3

      Review

      Local compliance.

      Healthcare Compliance 1 month

    4. 4

      Launch

      With field teams.

      Disease Network Specialist, Rare Endocrinology, EU Center 1 month

    5. 5

      Promote

      Congress and email.

      Director, Customer Engagement, International ongoing

    6. 6

      Measure

      Registrations.

      Associate Director, Omnichannel Analytics monthly

    First result
    1 year
    Cost
    Platform costs
    Owner
    Director, Customer Engagement, International

    Smallest test

    Launch one country page.

    Why it works

    Launch HCP portals in priority countries with localized disease education, testing routes and contacts, built from the modular content system and measured by registered HCPs.

    Local HCP portals let small country teams reach the doctors who see rare patients.

    Risks and how to handle them

    • Local regulations

      Country review.

    Evidence

    • HiringAssociate Director/Director Customer Engagement, International (Zug, posted October 13, 2026): owns "the International omnichannel customer engagement strategy across HCPs and patients", including "disease-awareness websites, HCP portals, email and marketing automation, and paid and organic social media"; sets "modular content requirements and localization guardrails"; pilots AI tools "in a compliant and measurable way". A Director, Sales Force Effectiveness, International was posted the same day.Source
    • Your websiteHomepage: "$8 billion peak year sales potential", "3 FDA approvals received" and "70+ published peer reviewed papers", with a footnote that Encaleret, BBP-418 and Infigratinib "have not yet received FDA or other regulatory approval"; links to the On Rare podcast and Insights; "This site is intended for U.S. residents." The only sign-up is a footer form, "Stay informed.", with one checkbox: "I agree to receive updates from BridgeBio" - no choice of audience or condition.Source
    • HiringDisease Network Specialist, Rare Endocrinology, EU Center (Germany, posted October 22, 2026): "improve the diagnosis rates of autosomal dominant hypocalcemia type 1 (ADH1)" with "a focus on disease education in the 2027 pre-launch phase"; share "guideline-aligned diagnostic algorithms"; support "the logistics of genetic testing, including family testing initiated by the treating physician". A Medical Science Liaison, a Market Access Manager and a Senior Director, Commercial are also being hired for the EU Center.Source

Wildcards 2

Unexpected experiments, each with a cheap way to test it.

  • 20

    The EU role mentions "family testing initiated by the treating physician". ADH1 is dominant and LGMD2I/R9 is recessive, so relatives may carry or have the condition. A doctor who diagnoses one patient is often the best route to family members.

    Medium impactLow effort First result in 1 quarter Medical Affairs

    First action

    Draft a family letter template.

    How to measure it

    Family tests

    Now
    –
    Target
    +30%
    By
    1 year

    Steps

    1. 1

      Draft letter

      Plain language.

      Medical Affairs 2 weeks

    2. 2

      Review

      Compliance.

      Healthcare Compliance 2 weeks

    3. 3

      Publish

      HCP testing pages.

      Digital Marketing team 1 week

    4. 4

      Train field

      How to share.

      Associate Director, Commercial Learning & Development 1 week

    5. 5

      Track

      Family tests.

      Associate Director, Omnichannel Analytics monthly

    6. 6

      Refine

      With genetic counselors.

      Medical Affairs quarterly

    First result
    1 quarter
    Cost
    Staff time only
    Owner
    Medical Affairs

    Smallest test

    Share the letter with five doctors.

    Why it works

    Give doctors a family testing pack: a plain-language letter patients can share with relatives, testing options and genetic counseling links, reviewed by Medical and Compliance.

    Family testing finds diagnoses that would otherwise take years.

    Risks and how to handle them

    • Privacy

      Patients choose whether to share.

    Evidence

    • HiringDisease Network Specialist, Rare Endocrinology, EU Center (Germany, posted October 22, 2026): "improve the diagnosis rates of autosomal dominant hypocalcemia type 1 (ADH1)" with "a focus on disease education in the 2027 pre-launch phase"; share "guideline-aligned diagnostic algorithms"; support "the logistics of genetic testing, including family testing initiated by the treating physician". A Medical Science Liaison, a Market Access Manager and a Senior Director, Commercial are also being hired for the EU Center.Source
    • Your websiteGenetic testing hub (checked October 23, 2026): rare disease patients "see an average of 7.3 physicians before receiving a correct diagnosis"; at-home and on-demand mobile testing; and a "BridgeBio Genetic Testing Tour Summer '26" panel listing west coast stops (Seattle to Phoenix) focused on ADH1 and hypoparathyroidism, still shown in late October with "We will be adding stops along the way".Source
    • Your websiteLGMD2I/R9 condition page: "7,000+ estimated individuals living with LGMD2I/R9 in the U.S. and Europe"; "As many as 10+ years to receive diagnosis due to variability of symptoms"; "Genetic testing is the only way to confirm a diagnosis of LGMD2I/R9."Source
  • 21

    The homepage shows "$8 billion peak year sales potential" next to patient stories, on a site "intended for U.S. residents". Patients and caregivers, doctors and investors all land on the same page, and the new media relations lead is asked for one coherent narrative.

    Medium impactLow effort First result in 1 month VP Global Media Relations & E…

    First action

    Add the four entry points.

    How to measure it

    Homepage bounce rate

    Now
    –
    Target
    -15%
    By
    60 days

    Steps

    1. 1

      Agree paths

      Four audiences.

      VP Global Media Relations & Executive Communications 1 week

    2. 2

      Design

      Top of page.

      Digital Marketing team 1 week

    3. 3

      Move figures

      To investors.

      VP Global Media Relations & Executive Communications 1 day

    4. 4

      Test

      Against current.

      Associate Director, Omnichannel Analytics 1 month

    5. 5

      Measure

      Path clicks.

      Associate Director, Omnichannel Analytics monthly

    6. 6

      Refine

      By audience.

      VP Global Media Relations & Executive Communications quarterly

    First result
    1 month
    Cost
    Staff time only
    Owner
    VP Global Media Relations & Executive Communications

    Smallest test

    Test entry points for two weeks.

    Why it works

    Add clear entry points at the top (patients and caregivers, healthcare professionals, investors, careers), move financial figures to the investor path, and lead the homepage with the mission and testing support.

    Visitors find what they came for faster, and the story matches the audience.

    Risks and how to handle them

    • Investors expect the figures

      Keep them one click away.

    Evidence

    • Your websiteHomepage: "$8 billion peak year sales potential", "3 FDA approvals received" and "70+ published peer reviewed papers", with a footnote that Encaleret, BBP-418 and Infigratinib "have not yet received FDA or other regulatory approval"; links to the On Rare podcast and Insights; "This site is intended for U.S. residents." The only sign-up is a footer form, "Stay informed.", with one checkbox: "I agree to receive updates from BridgeBio" - no choice of audience or condition.Source
    • HiringExecutive Director/VP Global Media Relations, Executive Communications & Comm Ops (posted October 13, 2026): "setting one coherent corporate narrative and adapting it across every market"; leads media around "clinical data readouts, regulatory milestones, earnings, and business development announcements".Source

03

How Programmable can help

Where an idea in this playbook is something Programmable builds or runs, it's listed here with what we'd do. Everything else is yours to run.

ProgrammableDigital

Show it, don't just describe it

These ideas need something to show: a demo, a video, an animation, graphics or a deck. Digital turns screenshots or the site into all of them, in the company's own brand.

Make a demo (opens programmable.digital in a new tab)
Website review of bridgebio.com More example playbooks and reviews

More growth playbooks

Other companies we have researched, each read from what they are hiring for.

  • BillionToOne growth strategyA Nasdaq-listed molecular diagnostics company with single-molecule counting technology: Unity prenatal screening (Unity Complete, Fetal…21 growth ideas
  • Phantom growth strategyA self-custodial crypto wallet and trading app for tokens, perps and prediction markets across Solana, Ethereum, Bitcoin and other…21 growth ideas
  • Double My Ecommerce growth strategyJoe Chavez's growth advisory practice: Meta ads, full-funnel strategy, CRO and subscription growth for Shopify brands, built on his Lead…21 growth ideas
  • LaunchDarkly growth strategyA runtime control platform: feature flags, progressive delivery, experimentation, observability and AgentControl for configuring…23 growth ideas
  • Albemarle growth strategyA global specialty chemicals company producing lithium compounds for batteries (Energy Storage), bromine flame retardants, amines and…21 growth ideas
  • Drata growth strategyAn agentic trust management platform: compliance automation for SOC 2, ISO 27001, HIPAA and more, third-party risk management, AI…22 growth ideas
  • The Orchard growth strategyA full-service music distribution and artist and label services company, part of Sony Music, offering distribution, marketing, sync…21 growth ideas
  • Consumer Reports growth strategyIndependent nonprofit testing and rating of 10,000+ products and services, consumer advocacy and investigations, funded by members and…21 growth ideas

See every playbook and website review

Independent research. Programmable wrote this playbook from public sources, as they stood on October 26, 2026, and cites them throughout. BridgeBio did not commission, review or endorse it, and Programmable is not affiliated with BridgeBio. Company and product names are trademarks of their owners, used only to identify them. The ideas are suggestions and opinion, not professional, legal or financial advice, and not statements about how BridgeBio runs its business.

Something wrong, or do you represent BridgeBio? Email [email protected] and we will correct it or take it down.

30/60/90 roadmap

What to focus on in each month, and the ideas that carry it.

  1. Days 1 to 308 ideas

    LGMD2I/R9 testing page, testing tour panel, audience sign-up, homepage weight, tag audit and the office access toolkit; start family testing materials and homepage entry points.

  2. Days 31 to 6010 ideas

    Clinic mapping, peer education, stories, modular content, German ADH1 page, community panel, rare-disease KPIs, payer insights, testing data series and podcast clips.

  3. Days 61 to 903 ideas

    Commit to a portfolio diagnosis service, a reusable launch kit and country HCP portals.

The research behind the plan

3 research areas, each summarised in a few lines. Open any of them for the full detail.

Customers

What customers say

Customers value science-led medicines for conditions with few options. The most cited problem: years-long diagnostic journeys.

  • No-cost genetic testing support
  • Insurance and prior authorization hurdles
  • In their words: “diagnostic journey”

Market

Competitive landscape

4 competitors compared: Pfizer (tafamidis), Alnylam (vutrisiran), BioMarin (Voxzogo) and Ascendis (Yorvipath).

  • Gap to exploit: Easy genetic testing for neuromuscular conditions
  • Pfizer (tafamidis): Large-company focus spread across many areas
  • Alnylam (vutrisiran): Different route of administration

Hiring signals

BridgeBio is staffing a multi-launch commercial machine.

  • Associate Director, HCP Marketing: Find doctors likely to see LGMD2I/R9; disease education. Ideas 1, 7, 8.
  • Director, Marketing - Achondroplasia Community: Community insights and ambassadors. Idea 12.
  • Associate Director, Omnichannel Analytics: Small audiences, complex journeys. Ideas 3, 5, 13.

From the team that wrote this playbook

All products
  • ProgrammableAgencyWorking AI systems in days, not quarters (opens programmable.agency in a new tab)
  • ProgrammableInfoAn agent that finds, researches and asks firstNew accounts get 100,000 free enrichment credits with code BETA100K (opens programmable.info in a new tab)
  • ProgrammableDigitalScreenshots in, an animated product demo out (opens programmable.digital in a new tab)
  • ProgrammableWatchKnow the day a supplier falls out of compliance (opens programmable.watch in a new tab)
  • ProgrammableTalkGet registrants for your events, and know who’s coming (opens programmable.talk in a new tab)
  • ProgrammableMediaAn AI note taker, interpreter and webinar host for your calls (opens programmable.media in a new tab)
  • ProgrammablePageText what you need, your customer gets a page that works (opens programmable.page in a new tab)
  • ProgrammableCommunityForums with labelled AI members, never empty (opens programmable.community in a new tab)
ProgrammableMarketing
ExamplesLeaderboardsProductsTermsPrivacyCookiesDPALegalContact

© 2026 AI-Powered Growth Intelligence